Career Opportunity

Sales Training & Development Specialist

Life Molecular Imaging (LMI) is a global, innovative R&D company focusing on the development and commercialization of molecular imaging radiopharmaceuticals for our approved F-18 amyloid PET tracer Neuraceq® and a pipeline of PET tracers in clinical development. Our vision is to create value for patients and physicians by improving early detection and characterization of chronic and life-threatening diseases leading to better therapeutic outcomes and improved quality of life.

Sales Training & Development Specialist

Candidates should live in the Eastern or Central Time Zones to support the business development throughout the US.

Enhance the competencies of sales and sales support employees by designing and conducting training programs that will boost workplace performance in alliance with company’s core values. You will be responsible for performing training needs assessments, designing, delivering, monitoring and evaluating curriculum and learning materials, and for managing all phases of training interventions.

Key Tasks and Responsibilities (not all inclusive):

  • Develop and implement comprehensive scalable training programs to support the development of the commercial sales team with the necessary skills and knowledge to compete in the market.
  • Work with employees, managers, human resources, and other departments to identify learning during the full employment lifecycle.
  • Conduct skill gap analysis to identify areas of improvement.
  • Determine instructional methods utilizing knowledge of specified training needs and effectiveness of such methods, such as individual training, group instruction, lectures, demonstrations, conferences, meetings, and workshops while staying within budget.
  • Create or source engaging and interactive training materials including presentations, e-learning modules, job aids or outside training.
  • Evaluate effectiveness of training and development programs and utilize relevant evaluation data to revise or recommend changes in instructional objectives and methods.
  • In collaboration with human resources, document skill gaps, training and outcomes. Assist with identifying applicable cross training for other departments.
  • Able to travel domestically up to 30%.
  • 3+ years previous, demonstrated success as a sales trainer or learning and development role with experience in design theory, development, facilitation, and learning principles.
  • Exceptional communication and presentation skills.
  • Strong knowledge of sales techniques and strategies.
  • Comprehensive knowledge of training plan curriculum, aid design and development.

What we expect:
At LMI, success stems from adaptability, resilience, and a commitment to our mission. We seek individuals who thrive in a dynamic, rapidly evolving environment and embrace the challenges and opportunities that come with growth. Our ideal candidates are proactive, solution-focused professionals who share our passion for advancing neuroimaging technology to transform the lives of patients affected by Alzheimer’s and other neurodegenerative diseases.

What you can expect:
A rewarding and challenging career with the support of their coworkers, managers, and other divisions of a global company. You will be able to make significant contributions through your expertise. You can expect what YOU do to matter, as all our employees are an integral part of a global organization as well as the communities we serve. The salary range for this position is $100-110,000, along with a competitive benefits package including medical, dental, vision, life & disability, 401k, and PTO.

Life Molecular Imaging, Inc. is an Equal Opportunity Employer. We believe what we do and our culture of “More Than a Job. It’s Making Life Better” extends to creating a welcoming, safe, and inclusive work environment. If you have what it takes and the passion to make a difference, please apply.

Apply here
Neuraceq® - Product Indications And Use

PRODUCT INDICATIONS AND USE: Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations.

Limitations: Limitations of Use
A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder. The safety and effectiveness of Neuraceq have not been established for Predicting the development of dementia or other neurologic conditions or monitoring responses to therapies.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS

  • Risk for Image Misinterpretation and other Errors
    Errors may occur in the Neuraceq estimation of brain neuritic β-amyloid plaque density during image interpretation [see Clinical Studies (14)]. Image interpretation should be performed independently of the patient’s clinical information. The use of clinical information in the interpretation of Neuraceq images has not been evaluated and may lead to errors. Errors may also occur in cases with severe brain atrophy that limits the ability to distinguish gray and white matter on the Neuraceq scan. Errors may also occur due to motion artifacts that result in image distortion. Neuraceq scan results are indicative of the presence of brain neuritic β-amyloid plaques only at the time of image acquisition and a negative scan result does not preclude the development of brain neuritic β-amyloid plaques in the future.
  • Radiation Risk
    Neuraceq, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration.

ADVERSE REACTIONS:

  • The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/appliucation site erythema (1.7%), injection site irritation (1.1%).

DRUG INTERACTIONS

  • Drug-drug interaction studies have not been performed in patients to establish the extent, if any, to which concomitant medications may alter Neuraceq image results.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: All radiopharmaceuticals, including Neuraceq, have a potential to cause fetal harm depending on the stage of fetal development and the magnitude of the radiopharmaceutical dose. If considering Neuraceq administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure.
  • Lactation: There are no data on the presence of florbetaben F 18 injection in human milk, the effects on the breastfed infant, or the effects of florbetaben F 18 injection on milk production. Exposure of Neuraceq to a breastfed infant can be minimized by temporary discontinuation of breastfeeding. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Neuraceq and any potential adverse effects on the breastfed child from Neuraceq or from the underlying maternal condition.
  • Pediatric Use: Neuraceq is not indicated for use in pediatric patients.
  • Geriatric Use: No overall differences in safety were observed between older and younger subjects

OVERDOSAGE
A pharmacological overdose of Neuraceq is unlikely given the relatively low doses used for diagnostic purposes. In the event of administration of a radiation overdose with Neuraceq, the absorbed organ dose to the patient should be reduced by increasing elimination of the radionuclide from the body by inducing frequent micturition. Prior to Neuraceq administration, please read the full Prescribing Information for additional Important Safety Information.

SUSPECTED ADVERSE REACTIONS please report to: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

.
.
.
.
.